Pharmacogenetics of Cardiac Inotropy

References

• Bers DM . Calcium cycling and signaling in cardiac myocytes . Annu. Rev. Physiol.70 , 23 – 49 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hasenfuss G , TeerlinkJR . Cardiac inotropes: current agents and future directions . Eur. Heart J.32 ( 15 ), 1838 – 1845 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A , RengoG , KochWJ . Adrenergic nervous system in heart failure: pathophysiology and therapy . Circ. Res.113 ( 6 ), 739 – 753 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hasenfuss G , PieskeB . Calcium cycling in congestive heart failure . J. Mol. Cell. Cardiol.34 ( 8 ), 951 – 969 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Holubarsch C , RufT , GoldsteinDJet al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels . Circulation94 ( 4 ), 683 – 689 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Teerlink JR , MetraM , ZacaVet al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond . Heart Fail. Rev.14 ( 4 ), 243 – 253 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A , RengoG , KochWJ . GRK2 inhibition in heart failure: something old, something new . Curr. Pharm. Des.18 ( 2 ), 186 – 191 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Brodde OE . Beta-adrenoceptors in cardiac disease . Pharmacol. Ther.60 ( 3 ), 405 – 430 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Colucci WS , WrightRF , BraunwaldE . New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments . N. Engl. J. Med.314 ( 6 ), 290 – 299 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Skeberdis VA , GendvilieneV , ZablockaiteDet al. Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current . J. Clin. Invest.118 ( 9 ), 3219 – 3227 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gauthier C , LeblaisV , KobzikLet al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle . J. Clin. Invest.102 ( 7 ), 1377 – 1384 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Rozec B , ErfanianM , LaurentK , TrochuJN , GauthierC . Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart . J. Am. Coll. Cardiol.53 ( 17 ), 1532 – 1538 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lohse MJ , EngelhardtS , EschenhagenT . What is the role of beta-adrenergic signaling in heart failure?Circ. Res.93 ( 10 ), 896 – 906 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Movsesian M , StehlikJ , VandeputF , BristowMR . Phosphodiesterase inhibition in heart failure . Heart Fail. Rev.14 ( 4 ), 255 – 263 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ather S , RespressJL , LiN , WehrensXH . Alterations in ryanodine receptors and related proteins in heart failure . Biochim. Biophys. Acta1832 ( 12 ), 2425 – 2431 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Brittsan AG , KraniasEG . Phospholamban and cardiac contractile function . J. Mol. Cell. Cardiol.32 ( 12 ), 2131 – 2139 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ludwig A , ZongX , JeglitschM , HofmannF , BielM . A family of hyperpolarization-activated mammalian cation channels . Nature393 ( 6685 ), 587 – 591 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Ohtsuki I , MorimotoS . Troponin: regulatory function and disorders . Biochem. Biophys. Res. Commun.369 ( 1 ), 62 – 73 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Despa S , BossuytJ , HanFet al. Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump function in cardiac myocytes . Circ. Res.97 ( 3 ), 252 – 259 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Daaka Y , LuttrellLM , LefkowitzRJ . Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A . Nature390 ( 6655 ), 88 – 91 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Salazar NC , VallejosX , SirykAet al. GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility . Cell Commun. Signal.11 , 64 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zhu W , PetrashevskayaN , RenSet al. Gi-biased β2AR signaling links GRK2 upregulation to heart failure . Circ. Res.110 ( 2 ), 265 – 274 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhu WZ , ZhengM , KochWJ , LefkowitzRJ , KobilkaBK , XiaoRP . Dual modulation of cell survival and cell death by β2-adrenergic signalling in adult mouse cardiomyocytes . Proc. Natl Acad. Sci. USA98 ( 4 ), 1607 – 1612 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Woo AY , XiaoRP . β-adrenergic receptor subtype signaling in heart: from bench to bedside . Acta Pharmacol. Sin.33 ( 3 ), 335 – 341 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd , TepeNM , LorenzJN , KochWJ , LiggettSB . Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice . Proc. Natl Acad. Sci. USA96 ( 11 ), 6400 – 6405 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , TepeNM , LorenzJNet al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level . Circulation101 ( 14 ), 1707 – 1714 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Reiter E , LefkowitzRJ . GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling . Trends Endocrinol. Metab.17 ( 4 ), 159 – 165 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ferguson SS . Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling . Pharmacol. Rev.53 ( 1 ), 1 – 24 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Rockman HA , KochWJ , LefkowitzRJ . Seven-transmembrane-spanning receptors and heart function . Nature415 ( 6868 ), 206 – 212 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Belmonte SL , BlaxallBC . G protein coupled receptor kinases as therapeutic targets in cardiovascular disease . Circ. Res.109 ( 3 ), 309 – 319 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Woodcock EA , DuXJ , ReicheltME , GrahamRM . Cardiac alpha1-adrenergic drive in pathological remodelling . Cardiovasc. Res.77 ( 3 ), 452 – 462 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Shannon R , ChaudhryM . Effect of alpha1-adrenergic receptors in cardiac pathophysiology . Am. Heart J.152 ( 5 ), 842 – 850 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Maltsev AV , KokozYM , EvdokimovskiiEV , PimenovOY , ReyesS , AlekseevAE . Alpha-2 adrenoceptors and imidazoline receptors in cardiomyocytes mediate counterbalancing effect of agmatine on NO synthesis and intracellular calcium handling . J. Mol. Cell. Cardiol.68C , 66 – 74 ( 2014 ).
   Google Scholar
• Philipp M , HeinL . Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes . Pharmacol. Ther.101 ( 1 ), 65 – 74 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A , RengoG , KochWJ . Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation . Trends Mol. Med.13 ( 12 ), 503 – 511 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Sandilands AJ , O’ShaughnessyKM , BrownMJ . Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta1-adrenoceptors versus Gly389 beta1-adrenoceptors in isolated human atrial myocardium . Br. J. Pharmacol.138 ( 2 ), 386 – 292 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Johnson JA , LiggettSB . Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions . Clin. Pharmacol. Ther.89 ( 3 ), 366 – 378 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mason DA , MooreJD , GreenSA , LiggettSB . A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor . J. Biol. Chem.274 ( 18 ), 12670 – 12674 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rathz DA , GregoryKN , FangY , BrownKM , LiggettSB . Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling . J. Biol. Chem.278 ( 12 ), 10784 – 10789 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Mialet Perez J , RathzDA , PetrashevskayaNNet al. Beta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure . Nat. Med.9 ( 10 ), 1300 – 1305 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , Mialet-PerezJ , Thaneemit-ChenSet al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure . Proc. Natl Acad. Sci. USA103 ( 30 ), 11288 – 11293 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Brodde OE . Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses . Pharmacol. Ther.117 ( 1 ), 1 – 29 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Leineweber K , BogedainP , WolfCet al. In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism . Naunyn. Schmiedebergs. Arch. Pharmacol.375 ( 5 ), 303 – 309 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Büscher R , BelgerH , EilmesKJet al. In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans . Pharmacogenetics11 ( 3 ), 199 – 205 ( 2001 ).
   PubMedGoogle Scholar
• O’Shaughnessy KM , FuB , DickersonC , ThurstonD , BrownMJ . The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects . Clin. Sci. (Lond.)99 ( 3 ), 233 – 238 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Snapir A , MikkelssonJ , PerolaM , PenttilaA , ScheininM , KarhunenPJ . Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death . J. Am. Coll. Cardiol.41 ( 2 ), 190 – 194 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A , BathgateA . Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown . Pharmacogenomics13 ( 3 ), 323 – 341 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd . Adrenergic signaling polymorphisms and their impact on cardiovascular disease . Physiol. Rev.90 ( 3 ), 1013 – 1062 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , CresciS , KellyRJet al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure . Nat. Med.14 ( 5 ), 510 – 517 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Small KM , WagonerLE , LevinAM , KardiaSL , LiggettSB . Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure . N. Engl. J. Med.347 ( 15 ), 1135 – 1142 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• O’Connor CM , FiuzatM , CarsonPEet al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms . PLoS ONE7 ( 10 ), e44324 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rababa’h A , CraftJWJr , WijayaCSet al. Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP) . J. Mol. Biol.425 ( 18 ), 3277 – 3288 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Marjamaa A , Laitinen-ForsblomP , WronskaA , ToivonenL , KontulaK , SwanH . Ryanodine receptor (RyR2) mutations in sudden cardiac death: studies in extended pedigrees and phenotypic characterization in vitro . Int. J. Cardiol.147 ( 2 ), 246 – 252 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Liu Y , KimlickaL , HiessFet al. The CPVT-associated RyR2 mutation G230C enhances store overload-induced Ca2+ release and destabilizes the N-terminal domains . Biochem. J.454 ( 1 ), 123 – 131 ( 2013 ).
   PubMedGoogle Scholar
• Jiang D , JonesPP , DavisDRet al. Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia . Channels (Austin)4 ( 4 ), 302 – 310 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Haghighi K , ChenG , SatoYet al. A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids . Hum. Mutat.29 ( 5 ), 640 – 647 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Santos DG , MedeirosA , BrumPCet al. No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure . BMC Cardiovasc. Disord.9 , 33 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• van der Zwaag PA , van RijsingenIA , AsimakiAet al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy . Eur. J. Heart Fail.14 ( 11 ), 1199 – 1207 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Haghighi K , PritchardT , BossuytJet al. The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase . J. Mol. Cell. Cardiol.52 ( 3 ), 773 – 782 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Haghighi K , KolokathisF , GramoliniAOet al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy . Proc. Natl Acad. Sci. USA103 ( 5 ), 1388 – 1393 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Biesiadecki BJ , KobayashiT , WalkerJSet al. The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation . Circ. Res.100 ( 10 ), 1486 – 1493 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO , von RichterOet al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo . Proc. Natl Acad. Sci. USA97 ( 7 ), 3473 – 3478 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Aarnoudse AJ , DielemanJP , VisserLEet al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration . Pharmacogenet. Genomics18 ( 4 ), 299 – 305 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Horinouchi M , SakaedaT , NakamuraTet al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin . Pharm. Res.19 ( 10 ), 1581 – 1585 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sakaeda T , NakamuraT , HorinouchiMet al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects . Pharm. Res.18 ( 10 ), 1400 – 1404 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Neuvonen AM , PaloJU , SajantilaA . Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users . Int. J. Legal Med.125 ( 2 ), 265 – 269 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hamilton RA , KowalskySF , WrightEMet al. Effect of the acetylator phenotype on amrinone pharmacokinetics . Clin. Pharmacol. Ther.40 ( 6 ), 615 – 619 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Antila S , PesonenU , LehtonenLet al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators . Eur. J. Pharm. Sci.23 ( 3 ), 213 – 222 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Sehnert AJ , DanielsSE , ElashoffMet al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol . J. Am. Coll. Cardiol.52 ( 8 ), 644 – 651 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Magnusson Y , LevinMC , EggertsenRet al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy . Clin. Pharmacol. Ther.78 ( 3 ), 221 – 231 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Cresci S , KellyRJ , CappolaTPet al. Clinical and genetic modifiers of long-term survival in heart failure . J. Am. Coll. Cardiol.54 ( 5 ), 432 – 444 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• McConnachie G , LangebergLK , ScottJD . AKAP signaling complexes: getting to the heart of the matter . Trends Mol. Med.12 ( 7 ), 317 – 323 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Van Petegem F . Ryanodine receptors: structure and function . J. Biol. Chem.287 ( 38 ), 31624 – 31632 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ran Y , ChenJ , LiN , ZhangWet al. Common RyR2 variants associate with ventricular arrhythmias and sudden cardiac death in chronic heart failure . Clin. Sci. (Lond.)119 ( 5 ), 215 – 223 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yano K , Zarain-HerzbergA . Sarcoplasmic reticulum calsequestrins: structural and functional properties . Mol. Cell. Biochem.135 ( 1 ), 61 – 70 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Priori SG , ChenSR . Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis . Circ. Res.108 ( 7 ), 871 – 883 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Di Barletta MR , Viatchenko-KarpinskiS , NoriAet al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia . Circulation114 ( 10 ), 1012 – 1019 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Wong CH , KooSH , SheGQ , ChuiP , LeeEJ . Genetic variability of RyR2 and CASQ2 genes in an Asian population . Forensic Sci. Int.192 ( 1–3 ), 53 – 55 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Napolitano C , AntzelevitchC . Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel . Circ. Res.108 ( 5 ), 607 – 618 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Huang YC , LinYJ , ChangJSet al. Single nucleotide polymorphism rs2229634 in the ITPR3 gene is associated with the risk of developing coronary artery aneurysm in children with Kawasaki disease . Int. J. Immunogenet.37 ( 6 ), 439 – 443 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kokubo Y , InamotoN , TomoikeHet al. Association of genetic polymorphisms of sodium-calcium exchanger 1 gene, NCX1, with hypertension in a Japanese general population . Hypertens. Res.27 ( 10 ), 697 – 702 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Xiao B , ZhangY , NiuW , GaoP , ZhuD . Association of ATP1B1 single-nucleotide polymorphisms with blood pressure and hypertension in a Chinese population . Clin. Chim. Acta407 ( 1–2 ), 47 – 50 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Craig R , LehmanW . Crossbridge and tropomyosin positions observed in native, interacting thick and thin filaments . J. Mol. Biol.311 ( 5 ), 1027 – 1036 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Solaro RJ , Van EykJ . Altered interactions among thin filament proteins modulate cardiac function . J. Mol. Cell. Cardiol.28 ( 2 ), 217 – 230 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Lu QW , WuXY , MorimotoS . Inherited cardiomyopathies caused by troponin mutations . J. Geriatr. Cardiol.10 ( 1 ), 91 – 101 ( 2013 ).
   PubMedGoogle Scholar
• Palm T , GraboskiS , Hitchcock-DeGregoriSE , GreenfieldNJ . Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region . Biophys. J.81 ( 5 ), 2827 – 2837 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kamisago M , SharmaSD , DePalmaSRet al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy . N. Engl. J. Med.343 ( 23 ), 1688 – 1696 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Willott RH , GomesAV , ChangANet al. Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? J. Mol. Cell. Cardiol. 48 ( 5 ), 882 – 892 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F , MorimotoS , HaradaKet al. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy . J. Mol. Cell. Cardiol.33 ( 12 ), 2095 – 2107 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Solaro RJ , RosevearP , KobayashiT . The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation . Biochem. Biophys. Res. Commun.369 ( 1 ), 82 – 87 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kobayashi T , SolaroRJ . Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I . J. Biol. Chem.281 ( 19 ), 13471 – 13477 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mogensen J , KuboT , DuqueMet al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations . J. Clin. Invest.111 ( 2 ), 209 – 216 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Takeda S , YamashitaA , MaedaKet al. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form . Nature424 ( 6944 ), 35 – 41 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Mogensen J , MurphyRT , ShawTet al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy . J. Am. Coll. Cardiol.44 ( 10 ), 2033 – 2040 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Landstrom AP , ParvatiyarMS , PintoJRet al. Molecular and functional characterization of novel hypertrophic cardio-myopathy susceptibility mutations in TNNC1-encoded troponin C . J. Mol. Cell. Cardiol.45 ( 2 ), 281 – 288 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Parvatiyar MS , LandstromAP , Figueiredo-FreitasCet al. A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation . J. Biol. Chem.287 ( 38 ), 31845 – 31855 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lehtonen LA , AntilaS , PentikäinenPJ . Pharmacokinetics and pharmacodynamics of intravenous inotropic agents . Clin. Pharmacokinet.43 ( 3 ), 187 – 203 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Talameh JA , LanfearDE . Pharmacogenetics in chronic heart failure: new developments and current challenges . Curr. Heart Fail. Rep.9 ( 1 ), 23 – 32 ( 2012 ).
   PubMedGoogle Scholar
• Heart Failure Society of America : HFSA 2010 comprehensive heart failure practice guideline . J. Card. Fail.16 ( 6 ), e1 – e194 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL , JordanJ , HofmannUet al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins . Clin. Pharmacol. Ther.86 ( 6 ), 605 – 608 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr , PattersonJH , GattisWAet al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis . J. Am. Coll. Cardiol.46 ( 3 ), 497 – 504 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Nieminen MS , FruhwaldS , HeunksLMet al. Levosimendan: current data, clinical use and future development . Heart Lung Vessel5 ( 4 ), 227 – 245 ( 2013 ).
   PubMedGoogle Scholar